- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04617067
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland, T12 DC4A
- Cork University Hospital
-
Limerick, Ireland, V94 F858
- University Hospital Limerick
-
Waterford, Ireland, X91 ER8E
- University Hospital Waterford
-
-
Dublin 24
-
Dublin, Dublin 24, Ireland, D24 NR04
- Tallaght University Hospital
-
-
Dublin 4
-
Dublin, Dublin 4, Ireland, D04 T6F4
- St. Vincent's University Hospital
-
-
Dublin 9
-
Dublin, Dublin 9, Ireland, D09V2N0
- Beaumont Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained prior to any study-related procedures.
- Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- No prior chemotherapy for incurable, locally advanced unresectable or metastatic pancreatic cancer. Patients may have received prior chemotherapy in the neo-adjuvant or adjuvant setting provided they have a minimum treatment-free interval of 3 months.
- At least one measurable lesion according to RECIST criteria (Version 1.1). Patients with bone only disease are not eligible.
- Aged 18 years or older
- ECOG performance status 0 - 2
Adequate haematological, renal and hepatic function measured within 28 days prior to commencing study:
- Total bilirubin ≤ ULN (or ≤ 3 x ULN (≤ grade 2) for patients with liver involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (≤ grade
1) (≤ 5 x ULN for patients with liver involvement by pancreatic cancer).
- Glomerular filtration rate (GFR) ≥ 30mL/min/1.73 m2 (≤ grade 2) for patients with serum creatinine levels above or below the institutional normal range. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with a Body Mass Index (BMI) >30 kg/m2, lean body weight should be used instead.
- Platelet count ≥ 100 x 109/L.
- Haemoglobin (Hb) ≥ 8 g/dL (≤ grade 2)
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≤ grade 1)
- Corrected serum calcium of ≤ 2.9 mmol/L (≤ grade 1).
- Life expectancy of at least 12 weeks.
Women of childbearing potential and sexually active males must agree to use highly effective contraceptive measures. This applies from starting treatment until at least 6 months after the last study drug administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:
i. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable). iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system (IUS). v. Bilateral tubal occlusion. vi. Successfully vasectomised partner. vii. Sexual abstinence.
Exclusion Criteria:
- Treated with other investigational drugs within 28 days or 5.5 half-lives of treatment start; in addition, concurrent alternative (complementary) medications are excluded within 28 days of treatment start.
- Known brain metastases, unless previously treated and well-controlled for at least 2 months.
- Dementia, altered mental status, or any other psychiatric condition that would interfere with the patient's safety or informed consent
- History of other malignancy other than pancreatic cancer. However, patients who have been disease free from another malignancy for at least 5 years, or patients with a history of resected non-melanoma skin cancer or successfully treated in situ cancer and superficial bladder tumours (Ta, Tis, T1) are eligible.
- Known history of hypercalcaemia.
- Presence or history of symptomatic kidney stones in the last 5 years.
- Active, clinically serious infections > grade 2 (CTCAE v5.0).
- Greater than or equal to grade 2 sensory or motor neuropathy
- Uncontrolled intercurrent illness, including, but not limited to uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or social situation that would affect compliance with the requirements of this study.
- GI tract disease resulting in an inability to take oral medications, malabsorption syndrome, where previous surgical procedures affect absorption and uncontrolled inflammatory bowel disease.
- History of diseases known to be associated with calcium disorders, including: ongoing hyperparathyroidism and Sarcoidosis.
- Hypersensitivity to any of the excipients of gemcitabine, Nab-paclitaxel or Paricalcitol.
- Known vitamin D toxicity
Undergoing treatment with the following therapies and medications:
- Concurrent use of drugs known to influence serum calcium such as thiazide diuretics, teriparatide (recombinant parathyroid hormone), calcitonin and multivitamin supplements containing > 400 IU of vitamin D or calcium.
- Current use of drugs which could influence bioavailability of paricalcitol (such as magnesium-containing antacids, bile-resin binders).
- Current use of strong inhibitors of CYP3A4 or CYP2C8.
- Current use of inducers of CYP3A4 or CYP2C8.
- Phosphate related medicinal products.
Note:
- Zoledronate or denosumab for patients with bone metastasis is allowed. Note patients with bone only disease are not eligible.
- Calcium intake is not restricted, but calcium supplementation is not permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All Patients
Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
|
Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 24 weeks from registration into the study
|
PFS is the percentage of patients free of progression at 24 weeks from registration into the study as determined by radiographic disease assessments per RECIST version 1.1.
|
24 weeks from registration into the study
|
Overall survival (OS)
Time Frame: 18 months post last patient registered
|
Overall survival (OS)
|
18 months post last patient registered
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to treatment failure
Time Frame: 18 months post last patient registered
|
Time to Treatment Failure (TTF) is defined as time from registration to discontinuation of therapy or add-on of new anti-cancer therapy for any reason (including death, progression and toxicity).
|
18 months post last patient registered
|
Tumour response rate Duration of response
Time Frame: 18 months post last patient registered
|
Confirmed tumour response rate as assessed by RECIST criteria version 1.1.
Duration of response (DR) as assessed by RECIST criteria version 1.1.
|
18 months post last patient registered
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: 18 months post last patient registered
|
Incidence of adverse events reported and toxicity evaluation as per the NCI CTCAE version 5.0
|
18 months post last patient registered
|
Incidence of hypercalcaemia
Time Frame: 18 months post last patient registered
|
Incidence of hypercalcaemia
|
18 months post last patient registered
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof. Bryan Hennessy, Beaumont Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Gemcitabine
Other Study ID Numbers
- CTRIAL-IE 19-33 (Other Identifier: Cancer Trials Ireland ID number)
- 2020-000073-24 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Pancreatic Cancer
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Danae Hamouda, MDRecruitingAdvanced Solid Tumor | Advanced Pancreatic CancerUnited States
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...United States
-
Centre Leon BerardRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerFrance
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerItaly
Clinical Trials on Paricalcitol
-
Abramson Cancer Center of the University of PennsylvaniaTerminated
-
AbbottCompletedRenal Insufficiency, ChronicUnited States, Poland
-
Cedars-Sinai Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingChronic PancreatitisUnited States
-
Chengdu Suncadia Medicine Co., Ltd.Not yet recruiting
-
AbbottCompletedRenal Insufficiency, ChronicUnited States, Poland
-
Cedars-Sinai Medical CenterAbbottCompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
Oslo University HospitalCompleted
-
Fresenius Medical Care North AmericaAbbottCompletedKidney FailureUnited States
-
AbbottCompletedRenal Insufficiency, ChronicUnited States, Poland
-
AbbottCompletedEnd Stage Renal Disease | Secondary HyperparathyroidismUnited States